Veronika Horvathova, MBChB, MSc

Associate Medical Director
hVivo Services LTD
London, England, United Kingdom

Disclosure: hVIVO Services Limited: Other Financial or Material Support, Employed by hVIVO during the conduct of the study.

Presentation(s):

• LB6 - EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

  Thursday, October 3
  2:35 PM – 2:45 PM